Hannah Lewis

Dr Hannah Lewis is a Senior Consultant at Scendea, working within the regulatory team. As part of her role, Hannah is responsible for the authoring and compilation of regulatory submissions to European and US agencies. Hannah also provides consulting and procedural support to clients within her role as project manager.

  • AdobeStock_433344680
    CPD Supplement

    Case Study- Luxturna

    2021-02-01T15:35:00

    The ATMP Luxturna (voretigene neparvovec) is a GTMP which utilises a recombinant adeno-associated viral vector serotype 2 (rAAV2) capsid as a delivery vehicle for the human retinal pigment epithelium 65 kDa protein (hRPE65) cDNA to the retina. Luxturna is approved for patients with retinal dystrophy associated with biallelic RPE65 mutations ...

  • AdobeStock_433344680
    CPD Supplement

    Understanding the basics of ATMP regulation

    2021-02-01T15:29:00

    Advanced therapy medicinal products (ATMPs) are biological products which comprise a diverse group of medicinal products that are often complex and diverse in nature. As these products are regularly developed for diseases of high unmet need, the requirements for evidence generation to support marketing authorisation often require innovative development plans. Within this continuing professional development supplement we investigate the regulation of ATMPs in the EU and US [see also Regulatory Rapporteur October 2020 and February 2020 for articles by Harriet Edwards on ATMPs].